Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18047580 | 1.00 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL697448 | 1.00 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL32662258 | 0.97 | ADAMTS4 (0.43) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL725182 | 0.79 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL5148621 | 0.79 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL29633569 | 0.79 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL8354666 | 0.79 | CA14 (0.39) | CA14CA2CA12 | |
| SCHEMBL15473444 | 0.79 | CA14 (0.39) | CA14CA2CA12 | |
| SCHEMBL5314799 | 0.77 | ADAMTS4 (0.43) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL19485860 | 0.77 | CA14 (0.38) | CA14CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | claimed |
| EP-3154989-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015191907-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2015-12-17 | — | — | WO | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| EP-2076490-A1 | CATHEPSIN B INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-07-08 | — | — | EP | disclosed |
| EP-2027143-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008037072-A1 | CATHEPSIN B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-04-03 | — | — | WO | disclosed |
| EP-1891003-A1 | FLUOROALKYLAMINE DERIVATIVES AS CATHEPSIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-02-27 | — | — | EP | disclosed |
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| WO-2006128287-A1 | FLUOROALKYLAMINE DERIVATIVES AS CATHEPSIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005016387-A2 | DNA-DEPENDENT MRI CONTRAST AGENTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0574135-B1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORP (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5644028-A | Process for producing peptide derivatives and salts therefor | JAPAN ENERGY CORPORATION (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0574135-A1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORPORATION (JP) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | ADAMTS4 90/4885HTT 1721/4885MMP1 127/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | ADAMTS4 90/4885HTT 1721/4885MMP1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.